{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"SELLAS Life Sciences Group, Inc. "},"Symbol":{"label":"Symbol","value":"SLS"},"Address":{"label":"Address","value":"15 WEST 38TH STREET,10TH FLOOR, NEW YORK, New York, 10017, United States"},"Phone":{"label":"Phone","value":"+1 917 438-4353"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax."},"CompanyUrl":{"label":"Company Url","value":"https://www.sellaslifesciences.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Angelos M. Stergiou","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}